Pharmaceutical

STAT+: Pharmalittle: FDA commish calls U.S. drug prices...

FDA Commissioner Robert Califf told a crowd of biotech leaders at the BIO conven...

Here’s why obesity grew so quickly worldwide, and where...

In high-income countries, such as the U.S., the rate of increase in BMI has actu...

Opinion: Why brain decoding is not mind reading — and w...

It is never too early to think about the ethical issues that can arise from any ...

Eli Lilly achieving significant gains in obesity results

The recent rallying of Lilly’s market value has come as the result of two major ...

US FDA expands approval for Merck’s PREVYMIS (letermovir)

The FDA approval was supported by a double-blind, active comparator-controlled n...

EC grants marketing authorisation for Fennec’s Pedmarqsi

The regulatory approval comes after a positive opinion issued by the European Me...

AstraZeneca ends Phase IV Andexxa trial after positive ...

The company will now seek full-label approval for the bleeding reversal agent in...

EU agencies back Covid-19 vaccine update ahead of autum...

Two EU agencies issued a statement on Covid-19 vaccine composition changes to in...

Baudax Bio reports promising additional data for neurom...

Shares rose for the company following data that favourably compares high-dose BX...

ZyVersa Therapeutics inches closer to European patent a...

VAR 200 reduces renal cholesterol and the lipid accumulation that damages the fi...

Fosun Pharma and IFC to build new drug manufacturing pl...

The new pharmaceutical production facility will manufacture five billion tablets...

FDA accepts GSK’s sBLA for Jemperli to treat endometria...

The sBLA was based on the prespecified interim analysis data from part one of th...

Acepodia raises funds to advance pipeline of cell thera...

Acepodia has raised $259m in venture capital, including $109m in a Series C fina...

STAT+: Biotech’s trade secrets face growing threat from...

Foreign influences pose a significant, growing threat to the early-stage work th...

STAT+: Biogen board and C-suite are in step as they eye...

As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&...

‘Tantamount to extortion’: Merck sues U.S. government o...

“This is not ‘negotiation.’ It is tantamount to extortion,” Merck wrote in its s...